Assembly Bio receives $10M from Gilead, Gilead buys 940,499 shares at $21.37

ASSEMBLY BIOSCIENCES, INC.

Gilead pays $10M upfront payment creditable against future collaboration obligations.
Opt-in fees for ABI-6250 restructured; total aggregate payments unchanged.
Gilead purchases 940,499 shares at $21.37/share, a 35% premium to 30-day VWAP.
Amendment redefines Phase 1b clinical trial and Triggering Clinical Trial for certain programs.
Additional Funding Payment of $10M due within [***] days; use restricted per Section 15.5(a).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.